<DOC>
	<DOCNO>NCT01720303</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial compare oral anti-diabetic drug ( OAD ) combine insulin vs. insulin alone subject type 2 diabetes adequately control current OAD therapy .</brief_summary>
	<brief_title>Efficacy Safety Repaglinide Combined With Insulin Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>HbA1c 7.5 % 13.0 % ( inclusive ) Fasting Cpeptide equal 0.33 nmol/l BMI ( Body Mass Index ) 25 32 kg/m2 ( inclusive ) Medical history treatment insulin within last 6 month Impaired renal function , define serum creatinine 1.7 mg/dl ( 150 Âµmol/l )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>